After ph2 win, Cerevance preps pivotal trials of novel Parkinson’s drug
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson’s disease drug CVN424 after hitting the mark in a phase […]
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson’s disease drug CVN424 after hitting the mark in a phase […]
By a narrow margin, an FDA advisory committee has voted against approval of Amylyx’ experimental medicine for amyotrophic lateral sclerosis until the company can provide […]
Shares in Amylyx Pharma slid today after the FDA published a less-than-enthusiastic assessment of its amyotrophic lateral sclerosis (ALS) therapy ahead of an advisory committee […]
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in […]
Shots: Teva to get an exclusive license globally to develop, manufacture & commercialize anle138b &sery433. Additionally, both companies will jointly develop the products for MSA […]
Already struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback after its tofersen drug for amyotrophic lateral […]
Biohaven’s key pipeline drug verdiperstat has failed to have any Therapeutic effect in patients with the rare neurological disorder multiple system atrophy (MSA) – its […]
It has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the merger has already had a setback. Alexion has […]
Ipsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took the helm last year, and a flurry […]
Startup PAQ Therapeutics is developing drugs work like Pac Man, gobbling up components of a cell associated with disease. The biotech has closed $30 million […]
UK artificial intelligence specialist Healx has begun a partnership with two medical charities that aims to uncover new therapies for the neurodegenerative disease Friedreich’s ataxia […]
Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany […]
Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen. Jennifer Doudna Scribe […]
Copyright © 2024 | WordPress Theme by MH Themes